Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model

T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy

(2017) Robert Sackstein et al.   LABORATORY INVESTIGATION

Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma

(2016) Jared Klarquist et al.   CANCER RESEARCH

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

(2016) A. Vasaturo et al.   CANCER RESEARCH

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

(2016) R. Andersen et al.   CLINICAL CANCER RESEARCH

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma

(2016) Sarah A. Weiss et al.   HUMAN PATHOLOGY

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

(2016) Carsten Denkert et al.   MODERN PATHOLOGY

Neoantigen landscape dynamics during human melanoma–T cell interactions

(2016) Els M. E. Verdegaal et al.   NATURE

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy

(2016) Maryann E. Mikucki et al.   OncoImmunology

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

(2015) M. E. Mikucki et al.   Nature Communications

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo

(2014) Erik Wennerberg et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Chemokines in Cancer

(2014) M. T. Chow et al.   Cancer Immunology Research

Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine

(2013) Anthony Rongvaux et al.   Annual Review of Immunology

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

(2013) D Bedognetti et al.   BRITISH JOURNAL OF CANCER

Overcoming Current Limitations in Humanized Mouse Research

(2013) Michael A. Brehm et al.   JOURNAL OF INFECTIOUS DISEASES

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy

(2012) Sivan Sapoznik et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

(2012) Eva Ellebaek et al.   Journal of Translational Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The pros and cons of chemokines in tumor immunology

(2012) Antonella Viola et al.   TRENDS IN IMMUNOLOGY

High endothelial venules (HEVs) in human melanoma lesions

(2012) Ludovic Martinet et al.   OncoImmunology

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

(2010) W. Peng et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

(2008) Khoi Q. Tran et al.   JOURNAL OF IMMUNOTHERAPY